Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Iuvantium
Thame, Oxfordshire, United Kingdomiuvantium.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Iuvantium is an Oxford-based biotech startup founded in late 2022, developing a novel inorganic adjuvant platform to precisely engineer immunogenicity. The company targets antimicrobial resistance by enabling next-generation vaccines and therapeutics through a disease and antigen agnostic approach. It has secured competitive funding from iiCON/Innovate UK to accelerate preclinical development, with animal studies as the next step. Early partnerships have been established with universities and hospitals; pharma collaborations are planned. The company’s technology aims to induce specific immune responses such as Th17 for infectious disease defense, with future applications in cancer therapy also envisioned.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Inorganic immune modulators/adjuvantsNext-generation vaccinesCell therapiesImmunotherapies
- Industry
- Biotech
02
Partnerships
Research partnerships with universities and hospitals established; pharma/biotech partnerships planned but not yet announced.Funding partnership/grant from iiCON via Innovate UK.
Beyond the preview
Go deeper on Iuvantium.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Iuvantium.